Related Experiment Videos
[Creatine kinase risk groups in acute myocardial infarct]
1Klinik für Innere Medizin Theodor Brugsch, Humboldt-Universität zu Berlin.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|November 1, 1989
Summary
Creatine kinase (CK) monitoring aids acute myocardial infarction risk assessment. CKmax levels effectively classify patients into risk groups, aligning with ejection fraction measurements for better patient care.
Area of Science:
- Cardiology
- Biochemistry
Context:
- Acute myocardial infarction (AMI) management requires precise risk stratification.
- Monitoring cardiac biomarkers like creatine kinase (CK) is crucial for patient care.
Purpose:
- To evaluate the clinical utility of creatine kinase maximum (CKmax) levels for risk stratification in acute myocardial infarction (AMI) patients.
- To compare CKmax-based risk classification with ejection fraction global measurements and electrocardiogram findings.
Summary:
- Risk groups were established based on CKmax levels (≤23, 23-40, 40-60, >60 µmol/l·s) and ejection fraction global (≤30%, 30-45%, 45-60%, >60%).
- Retrospective electrocardiogram (ECG) classification (non-Q-wave, Q-wave) was also performed.
- CKmax classification aligned well with ejection fraction, with only a minor discrepancy in 2.5% of patients during their first AMI, without misclassifying overall risk (slight, moderate, high).
Impact:
- CKmax monitoring provides a practical and reliable method for basic medical care risk assessment in AMI.
- This approach supports accurate patient grouping, potentially improving treatment strategies and outcomes.
- No patients identified as moderate or high risk in their first AMI were misclassified by CKmax or ejection fraction global assessments.